Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00842309 · ClinicalTrials.gov registry record · Early Phase 1
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 68
- Enrollment target
NCT00842309: Completed Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00842309 is a Early Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00842309, a Early Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive either DCS (n = 25) or placebo (n = 25) one hour prior to 8 of 10 behavior therapy sessions.
Interventions
- DRUG Placebo
- DRUG d-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2008-11 |
| Est. Completion | 2018-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00842309
The ClinicalTrials.gov registry entry for NCT00842309 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00842309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00842309 about?
NCT00842309 is a clinical study titled "D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder". The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive either DCS (n = 25) or placebo (n = 25) ...
What is the current status of trial NCT00842309?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 68 participants. The study started on 2008-11. Estimated completion is 2018-08.
What interventions are being tested in trial NCT00842309?
The interventions under investigation include: Placebo (DRUG), d-cycloserine (DRUG).
Who is sponsoring clinical trial NCT00842309?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.